Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Hypertension

Lowering blood pressure targets cuts cardiovascular disease deaths

Study shows treatment using lower blood pressure targets reduces chance of cardiovascular death by 43%.

A major US study has found intensive treatment to a target of 120mmHg significantly improves cardiovascular outcomes compared with a target of 140mmHg, as recommended by NICE. In the image, close up of a doctor taking a patient's blood pressure

Source: Shutterstock.com

Patients who received intensive BP lowering treatment were less likely to experience a cardiovascular event

The target for systolic blood pressure recommended by the National Institute for Health and Care Excellence is 140mmHg in patients aged under 80 years, but epidemiological studies have suggested a lower target may be preferable.

A major US study by The SPRINT Research group involving 9,361 hypertensive patients has found intensive treatment to a target of 120mmHg significantly improves cardiovascular outcomes compared with a target of 140mmHg.

The comparison was stopped 3.3 years into the planned 5 years of the trial after the data safety monitoring board found that intensively treated patients were 25% less likely to experience a cardiovascular event and 27% less likely to die from any cause. Participants in this arm of the trial were 43% less likely to die from a cardiovascular event.

The findings, published in The New England Journal of Medicine[1] (online, 9 November 2015), could have implications for quality and outcomes framework indicators in the UK, which currently reward GPs at a target of 150mmHg.

 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20200147

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Minor Illness or Major Disease

    Minor Illness or Major Disease

    This established textbook helps you differentiate between minor illnesses which can be safely managed in the pharmacy, and major diseases.

    £43.00Buy now
  • FASTtrack: Pharmacology

    FASTtrack: Pharmacology

    FASTtrack: Pharmacology is a study guide providing an account of drug action, as well as dealing with molecular pharmacology at a more advanced level.

    £25.00Buy now
  • Introduction to Pharmaceutical Calculations

    Introduction to Pharmaceutical Calculations

    Introduction to Pharmaceutical Calculations is an essential study aid for pharmacy students. The book contains worked examples and sample questions and answers.

    £33.00Buy now
  • Lecture Notes in Pharmacy Practice

    Lecture Notes in Pharmacy Practice

    A comprehensive study guide which summarises the basic principles in pharmacy practice. Clear, bulleted information for quick reference.

    £43.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • A major US study has found intensive treatment to a target of 120mmHg significantly improves cardiovascular outcomes compared with a target of 140mmHg, as recommended by NICE. In the image, close up of a doctor taking a patient's blood pressure

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.